Search NASA⌕ Search

Engineering topics

Followill, D

Publications and source records attributed to Followill, D.

At least 55 records · Page 3

SU-F-BRE-14: Uncertainty Analysis for Dose Measurements Using OSLD NanoDots

Purpose: Optically stimulated luminescent dosimeters (OSLD) are an increasingly popular dosimeter for research and clinical applications. It is also used by the Radiological Physics Center for remote auditing of machine output. In this work we robustly calculated the reproducibility and uncertainty of the OSLD nanoDot. Methods: For the RPC dose calculation, raw readings are corrected for depletion, element sensitivity, fading, linearity, and energy. System calibration is determined for the experimental OSLD irradiated at different institutions by using OSLD irradiated by the RPC under reference conditions (i.e., standards): 1 Gy in a Cobalt beam. The intra-dot and inter-dot reproducibilities (coefficient of variation) were determined from the history of RPC readings of these standards. The standard deviation of the corrected OSLD signal was then calculated analytically using a recursive formalism that did not rely on the normality assumption of the underlying uncertainties, or on any type of mathematical approximation. This analytical uncertainty was compared to that empirically estimated from >45,000 RPC beam audits. Results: The intra-dot variability was found to be 0.59%, with only a small variation between readers. Inter-dot variability was found to be 0.85%. The uncertainty in each of the individual correction factors was empirically determined. When the raw counts from each OSLD were adjusted for the appropriate correction factors, the analytically determined coefficient of variation was 1.8% over a range of institutional irradiation conditions that are seen at the RPC. This is reasonably consistent with the empirical observations of the RPC, where the coefficient of variation of the measured beam outputs is 1.6% (photons) and 1.9% (electrons). Conclusion: OSLD nanoDots provide sufficiently good precision for a wide range of applications, including the RPC remote monitoring program for megavoltage beams. This work was supported by PHS grant CA10953 awarded by the NIH (DHHS)

60 APPLIED LIFE SCIENCES↗

MO-G-BRE-02: A Survey of IMRT QA Practices for More Than 800 Institutions

Purpose: A wide range of techniques and measurement devices are employed for IMRT QA, causing a large variation of accepted action limits and potential follow up for failing plans. Such procedures are not well established or accepted in the medical physics community. To achieve the goal of proving insight into current IMRT QA practices, we created an electronic IMRT QA survey. The survey was open to a variety of the most common QA devices and assessed the type of comparison to measurement, action limits, delivery methods, and clinical action for failing QA plans. Methods: We conducted an online survey through the Radiological Physics Center's (RPC) annual survey with the goal of ascertaining elements of routine patient-specific IMRT QA. A total of 874 institutions responded to the survey. The questions ranged from asking for action limits, dosimeter type(s) used, delivery techniques, and actions taken when a plan fails IMRT QA. Results: The most common (52%) planar gamma criteria was 3%/3 mm with a 95% of pixels passing criteria. The most common QA device were diode arrays (48%). The most common first response to a plan failing QA was to re-measure at the same point the point dose (89%), second was to re-measure at a new point (13%), and third was to analyze the plan in relative instead of absolute mode (10%) (Does not add to 100% as not all institutions placed a response for each QA follow-up option). Some institutions, however, claimed that they had never observed a plan failure. Conclusion: The survey provided insights into the way the community currently performs IMRT QA. This information will help in the push to standardize action limits among dosimeters.

60 APPLIED LIFE SCIENCES↗

MO-G-BRF-09: Investigating Magnetic Field Dose Effects in Mice: A Monte Carlo Study

Purpose: In MRI-linac treatments, radiation dose distributions are affected by magnetic fields, especially at high-density/low-density interfaces. Radiobiological consequences of magnetic field dose effects are presently unknown; therefore, preclinical studies are needed to ensure the safe clinical use of MRI-linacs. This study investigates the optimal combination of beam energy and magnetic field strength needed for preclinical murine studies. Methods: The Monte Carlo code MCNP6 was used to simulate the effects of a magnetic field when irradiating a mouse-sized lung phantom with a 1.0cmx1.0cm photon beam. Magnetic field effects were examined using various beam energies (225kVp, 662keV[Cs-137], and 1.25MeV[Co-60]) and magnetic field strengths (0.75T, 1.5T, and 3T). The resulting dose distributions were compared to Monte Carlo results for humans with various field sizes and patient geometries using a 6MV/1.5T MRI-linac. Results: In human simulations, the addition of a 1.5T magnetic field caused an average dose increase of 49% (range:36%–60%) to lung at the soft tissue-to-lung interface and an average dose decrease of 30% (range:25%–36%) at the lung-to-soft tissue interface. In mouse simulations, the magnetic fields had no effect on the 225kVp dose distribution. The dose increases for the Cs-137 beam were 12%, 33%, and 49% for 0.75T, 1.5T, and 3.0T magnetic fields, respectively while the dose decreases were 7%, 23%, and 33%. For the Co-60 beam, the dose increases were 14%, 45%, and 41%, and the dose decreases were 18%, 35%, and 35%. Conclusion: The magnetic field dose effects observed in mouse phantoms using a Co-60 beam with 1.5T or 3T fields and a Cs-137 beam with a 3T field compare well with those seen in simulated human treatments with an MRI-linac. These irradiator/magnet combinations are suitable for preclinical studies investigating potential biological effects of delivering radiation therapy in the presence of a magnetic field. Partially funded by Elekta.

60 APPLIED LIFE SCIENCES↗

TU-C-BRE-03: Aggregation of Linac Measurement Data

Purpose: Accurate data of linear accelerator radiation characteristics is important for treatment planning system commissioning as well as regular quality assurance of the machine. The RPC has performed site visits of numerous machines . Data gathered from Varian machines from the past 15 years are presented. The data collected can be used as a secondary check or when commissioning a new machine to verify that values are reasonable. Methods: Data from the past 15 years of RPC site visits was compiled and analyzed. Data was composed from measurements from approximately 400 Varian machines. Each dataset consists of several point measurements at various locations in a water phantom to measure percentage depth dose, output factors, including small MLC fields, off-axis factors, and wedge factors if applicable. Common statistical values are presented for each machine type. Where applicable, data was compared to other reference data given by the vendor or a select number of previous researchers. Results: Data is separated by energy and parameter and then analyzed by machine class. Data distributions of the parameter data were normal except occasionally at the tails. Distributions of the data for each class and parameter are tabulated to give not simply a singular reference value, but metrics about the distribution: 5th and 95th percentile values and the standard deviation as well as the median. Conclusion: The RPC has collected numerous data on Varian linacs and presented the finding of the past 15 years. The data can be used as a reference data set for physicists to compare against. A linac that deviates from the values does not necessarily indicate there is a problem as long as the treatment planning system correlates to the machine. Comparison of linac and treatment planning system data to external reference data can prevent serious treatment errors.

07 ISOTOPE AND RADIATION SOURCES↗

TU-C-BRE-09: Performance Comparisons of Patient Specific IMRT QA Methodologies Using ROC Analysis

Purpose: To evaluate the ability of a selection of patient-specific QA methods to accurately classify IMRT plans as acceptable or unacceptable based on a multiple ion chamber (MIC) phantom. Methods: Twenty-four IMRT plans were selected (20 previously failed the institutional QA), and were measured on a MIC phantom to assess their dosimetric acceptability. These same plans were then measured using film (Kodak EDR2) and ion chamber (Wellhofer cc04), ArcCheck (Sun Nuclear), and MapCheck (Sun Nuclear) (delivered AP field-by-field, AP composite, and with original gantry angles). All gamma analyses were performed at 2%/2mm, 3%/3mm, and 5%/3mm. By using the MIC results as a gold standard, the sensitivity and specificity were calculated across a range of cut-off thresholds (% pixels passing for gamma analysis, and % dose difference for ion chamber), and were used to form ROC curves. Area under the curve (AUC) was used as a metric to quantify the performance of the various QA methods. Results: Grouping device’s AUC’s revealed two statistically significant different groups: ion chamber (AUC of 0.94), AP composite MapCheck (AUC of 0.85), ArcCheck (AUC of 0.84), and film (AUC of 0.82) were in the better performing group, while original gantry angles and AP field-by-field MapCheck (AUC of 0.65 and 0.66, respectively) matched less well with the gold standard results. Optimal cut-offs were also assessed using the ROC curves. We found that while often 90% of pixels passing is used as a criteria, the differing sensitivities of QA methods can lead to device and methodology-based optimal cutoff thresholds. Conclusion: While many methods exist to perform the same task of patient-specific IMRT QA, they utilize different strategies. This work has shown that there are inconsistencies in these methodologies in terms of their sensitivity and specificity to dosimetric acceptability. This work was supported by Public Health Service grants CA010953, CA081647, and CA21661 awarded by the National Cancer Institute, United States Department of Health and Human Services.

60 APPLIED LIFE SCIENCES↗

TU-C-9A-01: IROC Organization and Clinical Trial Credentialing

As a response to recommendations from a report from the Institute of Medicine, NCI is reorganizing it clinical trial groups into a National Clinical Trial Network (NCTN) that consists of four adult groups (Alliance, ECOGACRIN, NRG, and SWOG) and one children’s group (COG). NRG will house CIRO, a center to promote innovative radiation therapy research and intergroup collaboration in radiation. The quality assurance groups that support clinical trials have also been restructured. ITC, OSU Imaging corelab, Philadelphia Imaging core-lab, QARC, RPC, and RTOGQA have joined together to create the Imaging and Radiation Oncology Core (IROC) Group. IROC’s mission is to provide integrated radiation oncology and diagnostic imaging quality control programs in support of the NCI’s NCTN thereby assuring high quality data for clinical trials designed to improve the clinical outcomes for cancer patients worldwide. This will be accomplished through five core services: site qualification, trial design support, credentialing, data management, case review.These changes are important for physicist participating in NCI clinical trials to understand. We will describe in detail the IROC’s activities and five core services so that as a user, the medical physicist can learn how to efficiently utilize this group. We will describe common pitfalls encountered in credentialing for current protocols and present methods to avoid them. These may include the which benchmarks are required for NSABP B-51/RTOG 1304 and how to plan them as well as tips for phantom planning. We will explain how to submit patient and phantom cases in the TRIAD system used by IROC. Learning Objectives: To understand the basic organization of IROC, its mission and five core services To learn how to use TRIAD for patient and phantom data submission To learn how to avoid common pitfalls in credentialing for current trials.

60 APPLIED LIFE SCIENCES↗

WE-D-18A-01: Evaluation of Three Commercial Metal Artifact Reduction Methods for CT Simulations in Radiation Therapy Treatment Planning

Purpose: To evaluate three commercial metal artifact reduction methods (MAR) in the context of radiation therapy treatment planning. Methods: Three MAR strategies were evaluated: Philips O-MAR, monochromatic imaging using Gemstone Spectral Imaging (GSI) dual energy CT, and monochromatic imaging with metal artifact reduction software (GSIMARs). The Gammex RMI 467 tissue characterization phantom with several metal rods and two anthropomorphic phantoms (pelvic phantom with hip prosthesis and head phantom with dental fillings), were scanned with and without (baseline) metals. Each MAR method was evaluated based on CT number accuracy, metal size accuracy, and reduction in the severity of streak artifacts. CT number difference maps between the baseline and metal scan images were calculated, and the severity of streak artifacts was quantified using the percentage of pixels with >40 HU error (“bad pixels”). Results: Philips O-MAR generally reduced HU errors in the RMI phantom. However, increased errors and induced artifacts were observed for lung materials. GSI monochromatic 70keV images generally showed similar HU errors as 120kVp imaging, while 140keV images reduced errors. GSI-MARs systematically reduced errors compared to GSI monochromatic imaging. All imaging techniques preserved the diameter of a stainless steel rod to within ±1.6mm (2 pixels). For the hip prosthesis, O-MAR reduced the average % bad pixels from 47% to 32%. For GSI 140keV imaging, the percent of bad pixels was reduced from 37% to 29% compared to 120kVp imaging, while GSI-MARs further reduced it to 12%. For the head phantom, none of the MAR methods were particularly successful. Conclusion: The three MAR methods all improve CT images for treatment planning to some degree, but none of them are globally effective for all conditions. The MAR methods were successful for large metal implants in a homogeneous environment (hip prosthesis) but were not successful for the more complicated case of dental artifacts.

60 APPLIED LIFE SCIENCES↗

SU-C-BRD-07: The Radiological Physics Center (RPC): 45 Years of Improving Radiotherapy Dosimetry

Purpose: The RPC, established in 1968 has contributed to the development, conduct, and QA of NCI funded multi-institutional cooperative group clinical trials and institutions, primarily in the USA/Canada and 242 other countries, participating in trials. Methods: The RPC QA program components were designed to audit the radiation dose calculation chain from the NIST traceable reference beam calibration, to inclusion of dosimetry parameters used to calculate tumor doses, to the delivery of the radiation dose. The QA program included: 1) remote TLD/OSLD audit of machine output, 2) on-site dosimetry review visits, 3) credentialing for advanced technologies, and 4) review of patient treatment records. The RPC presented and published their findings to the radiation oncology community. Results: The number of institutions monitored by the RPC increased from around 1200 in the late 90s, to ∼2000 in 2013. There were over 4000 megavoltage therapy machines and ∼28,000 therapy beams in the 1991 institutions monitored by the RPC by the end of 2013. Within the 14,000 photon, electron and proton beam outputs remotely monitored with TLD/OSLD annually, between 10-20% of the institutions have one or more beams outside the RPC 5% criterion. Dosimetry site visits to photon and proton centers continue to result in 2-4 recommendations affecting key dosimetry parameters that impact patient treatment times. One in four patient treatment records reviewed by the RPC have their dose data corrected by >5% before trial groups use them for outcomes analysis. Twelve of fourteen clinically active proton centers are approved to participate in NCI funded clinical trials. The RPC published 222 peer reviewed articles since 1972. Conclusion: Findings from the RPC suggest that human errors continue to play a role in radiotherapy discrepancies and without the RPC independent QA program, the number of undetected errors and time elapsed before their discovery would have been greater. Work supported by MGH C06 CA059267 and grants CA10953, CA081647 awarded by NCI, DHHS.

60 APPLIED LIFE SCIENCES↗

SU-E-P-02: Imaging and Radiation Oncology Core (IROC) Houston QA Center (RPC) Credentialing

Purpose: To provide information pertaining to IROC Houston QA Center's (RPC) credentialing process for institutions participating in NCI-sponsored clinical trials. Methods: IROC Houston issues credentials for NCI sponsored study groups. Requirements for credentialing might include any combination of questionnaires, knowledge assessment forms, benchmarks, or phantom irradiations. Credentialing requirements for specific protocols can be found on IROC Houston's website (irochouston.mdanderson.org). The website also houses the credentialing status inquiry (CSI) form. Once an institution has reviewed the protocol's credentialing requirements, a CSI form should be completed and submitted to IROC Houston. This form is used both to request whether requirements have been met as well as to notify IROC Houston that the institution requests credentialing for a specific protocol. IROC Houston will contact the institution to discuss any delinquent requirements. Once the institution has met all requirements IROC Houston issues a credentialing letter to the institution and will inform study groups and other IROC offices of the credentials. Institutions can all phone the IROC Houston office to initiate credentialing or ask any credentialing related questions. Results: Since 2010 IROC has received 1313 credentialing status inquiry forms. We received 317 in 2010, 266 in 2011, 324 in 2012, and 406 in 2013. On average we receive 35 phone calls per week with multiple types of credentialing questions. Decisions regarding credentialing status are based on the protocol specifications and previous completed credentialing by the institution. In some cases, such as for general IMRT credentialing, up to 5 sites may be credentialed based on the credentialing of one main center. Each of these situations is handled individually. Conclusion: IROC Houston will issue radiation therapy credentials for the NCI trials in the National Clinical Trials Network. Credentialing requirements and the CSI form can be found online at the IROC Houston's website. Work supported by PHS grant CA10953 and CA081647 (NCI, DHHS)

60 APPLIED LIFE SCIENCES↗

SU-E-J-189: Credentialing of IGRT Equipment and Processes for Clinical Trials

Purpose: Current dosimetry phantoms used for clinical trial credentialing do not directly assess IGRT processes. This work evaluates a custom-built IGRT phantom for credentialing of multiple IGRT modalities and processes. Methods: An IGRT phantom was built out of a low-density body with two inserts. Insert A is used for the CT simulation. Insert B is used for the actual treatment. The inserts contain identical targets in different locations. Relative positions are unknown to the user. The user simulates the phantom (with insert A) as they would a patient, including marking the phantom. A treatment plan is created and sent to the treatment unit. The phantom (with insert B) is then positioned using local IGRT practice. Shifts (planned isocenter, if applicable, and final isocenter) are marked on the phantom using room lasers. The mechanical reproducibility of re-inserting the inserts within the phantom body was tested using repeat high-resolution CT scans. The phantom was tested at 7 centers, selected to include a wide variety of imaging equipment. Results: Mechanical reproducibility was measured as 0.5-0.9mm, depending on the direction. Approaches tested to mark (and transfer) simulation isocenter included lasers, fiducials and reflective markers. IGRT approaches included kV imaging (Varian Trilogy, Brainlab ExacTrac), kV CT (CT-on-rails), kV CBCT (Varian Trilogy, Varian Truebeam, Elekta Agility) and MV CT (Tomotherapy). Users were able to successfully use this phantom for all combinations of equipment and processes. IGRT-based shifts agreed with the truth within 0.8mm, 0.8mm and 1.9mm in the LR, AP, and SI directions, respectively. Conclusion: Based on these preliminary results, the IGRT phantom can be used for credentialing of clinical trials with an action level of 1mm in AP and LR directions, and 2mm in the SI direction, consistent with TG142. We are currently testing with additional institutions with different equipment and processes, including Cyberknife. This project was funded by the Cancer Prevention Research Institute of Texas.

60 APPLIED LIFE SCIENCES↗

SU-E-T-87: Comparison Study of Dose Reconstruction From Cylindrical Diode Array Measurements, with TLD Measurements and Treatment Planning System Calculations in Anthropomorphic Head and Neck and Lung Phantoms

Purpose: To assess dose calculated by the 3DVH software (Sun Nuclear Systems, Melbourne, FL) against TLD measurements and treatment planning system calculations in anthropomorphic phantoms. Methods: The IROC Houston (RPC) head and neck (HN) and lung phantoms were scanned and plans were generated using Eclipse (Varian Medical Systems, Milpitas, CA) following IROC Houston procedures. For the H and N phantom, 6 MV VMAT and 9-field dynamic MLC (DMLC) plans were created. For the lung phantom 6 MV VMAT and 15 MV 9-field dynamic MLC (DMLC) plans were created. The plans were delivered to the phantoms and to an ArcCHECK (Sun Nuclear Systems, Melbourne, FL). The head and neck phantom contained 8 TLDs located at PTV1 (4), PTV2 (2), and OAR Cord (2). The lung phantom contained 4 TLDs, 2 in the PTV, 1 in the cord, and 1 in the heart. Daily outputs were recorded before each measurement for correction. 3DVH dose reconstruction software was used to project the calculated dose to patient anatomy. Results: For the HN phantom, the maximum difference between 3DVH and TLDs was -3.4% and between 3DVH and Eclipse was 1.2%. For the lung plan the maximum difference between 3DVH and TLDs was 4.3%, except for the spinal cord for which 3DVH overestimated the TLD dose by 12%. The maximum difference between 3DVH and Eclipse was 0.3%. 3DVH agreed well with Eclipse because the dose reconstruction algorithm uses the diode measurements to perturb the dose calculated by the treatment planning system; therefore, if there is a problem in the modeling or heterogeneity correction, it will be carried through to 3DVH. Conclusion: 3DVH agreed well with Eclipse and TLD measurements. Comparison of 3DVH with film measurements is ongoing. Work supported by PHS grant CA10953 and CA81647 (NCI, DHHS)

60 APPLIED LIFE SCIENCES↗

SU-E-T-110: Development of An Independent, Monte Carlo, Dose Calculation, Quality Assurance Tool for Clinical Trials

Purpose: To develop a comprehensive end-to-end test for Varian's TrueBeam linear accelerator for head and neck IMRT using a custom phantom designed to utilize multiple dosimetry devices. Purpose: To commission a multiple-source Monte Carlo model of Elekta linear accelerator beams of nominal energies 6MV and 10MV. Methods: A three source, Monte Carlo model of Elekta 6 and 10MV therapeutic x-ray beams was developed. Energy spectra of two photon sources corresponding to primary photons created in the target and scattered photons originating in the linear accelerator head were determined by an optimization process that fit the relative fluence of 0.25 MeV energy bins to the product of Fatigue-Life and Fermi functions to match calculated percent depth dose (PDD) data with that measured in a water tank for a 10x10cm2 field. Off-axis effects were modeled by a 3rd degree polynomial used to describe the off-axis half-value layer as a function of off-axis angle and fitting the off-axis fluence to a piecewise linear function to match calculated dose profiles with measured dose profiles for a 40×40cm2 field. The model was validated by comparing calculated PDDs and dose profiles for field sizes ranging from 3×3cm2 to 30×30cm2 to those obtained from measurements. A benchmarking study compared calculated data to measurements for IMRT plans delivered to anthropomorphic phantoms. Results: Along the central axis of the beam 99.6% and 99.7% of all data passed the 2%/2mm gamma criterion for 6 and 10MV models, respectively. Dose profiles at depths of dmax, through 25cm agreed with measured data for 99.4% and 99.6% of data tested for 6 and 10MV models, respectively. A comparison of calculated dose to film measurement in a head and neck phantom showed an average of 85.3% and 90.5% of pixels passing a 3%/2mm gamma criterion for 6 and 10MV models respectively. Conclusion: A Monte Carlo multiple-source model for Elekta 6 and 10MV therapeutic x-ray beams has been developed as a quality assurance tool for clinical trials.

60 APPLIED LIFE SCIENCES↗

SU-E-T-167: Evaluation of Mobius Dose Calculation Engine Using Out of the Box Preconfigured Beam Data

Purpose: Determine the dose calculation accuracy of a preconfigured Mobius server for use in secondary checks of a treatment planning system. Methods: 10 plans were created for irradiation on two of the IROC (formerly RPC) accreditation phantoms: 4 for the head and neck phantom and 6 for the lung phantom. The plans each were created using one of four different photon energies (6FFF, 10 FFF, 6X, and 15X) and were varied in treatment type including VMAT, step and shoot IMRT, dynamic MLC IMRT (DMLC), and conformal RT (CRT). The TLDs in the phantoms were contoured, and each plan was sent for calculation to Mobius software (Mobius Medical Systems, Houston, TX) with a default configuration. Each plan was then irradiated on the planned phantom 3 times to create an average reading across 56 TLDs. These readings were then compared against the corresponding Mobius calculation at each TLD location. Results: The mean difference (MD) normalized to the plan prescription dose between each TLD and Mobius calculation for all measurements was 0.5 ± 3.3%, with a maximum difference of 8.4%. The MD was 0.6 ± 3.8%, − 2.0 ± 1.9%, 1.7 ± 3.7%, and 1.9 ± 1.2% across the 6FFF, 10FFF, 6X and 15X energies respectively. The MD was −1.2 ± 2.3% for lung plans and 1.8 ± 3.5% for head/neck plans. Across treatment types, the MD ranged from − 1.8 ± 1.7% for CRT to 4.3 ± 2.4 % for DMLC. Conclusion: Out of the box and preconfigured, Mobius provides accurate dose calculations with respect to beam energy, treatment type, and treatment site.

60 APPLIED LIFE SCIENCES↗

SU-E-T-173: Evaluation of the MicroSTAR Reader for the OSLD System for Remote Dosimetry Audits at the IROC HQAC

Purpose: Analysis of the performance of the microSTARii reader for optically stimulated luminescence dosimeters (OSLD) used by the IROC Houston Quality Assurance Center (IROC HQAC) for external audits compare to the characteristics of the Microstar reader. Methods: The IROC HQAC uses the Microstar reader for the OSLD program for verification of output of photon, electron and proton beams. The calculation of dose from the OSLD system is based on a group of factors defined at time of the commissioning of a batch of detectors. Factors like system sensitivity (SS), depletion (KD), element correction factor (ECF), linearity (KL), energy correction (KE). The new microSTARii unit presents many hardware and software upgrades that were considered useful for this program. Based on these changes many factors, that were considered reader dependent, were revised in order to analyze the effect of the new reading process. The SS, KD, ECF and KL were evaluated and compared with data defined based on reading done on Microstar reader. Results: The SS is reader specific and specified at 100 cGy dose level. This value is define per reading session and monitored over time. The KD factor was found to be different because of reading procedure are different. The ECF values changed for a group of nano dots compare to values defined based on reading done on the Microstar reader. The KL was defined for the reader. Conclusion: The new microSTARii reader presents new features that improve the efficiency of the OSLD program at the IROC HQAC. New characterization is needed before final implementation is done to match the requirements of the existing OSLD system defined for the Microstar reader. Changes in uncertainty of the results has not been analized.

07 ISOTOPE AND RADIATION SOURCES↗

SU-E-T-192: FMEA Severity Scores - Do We Really Know?

Purpose: Failure modes and effects analysis (FMEA) is a subjective risk mitigation technique that has not been applied to physics-specific quality management practices. There is a need for quantitative FMEA data as called for in the literature. This work focuses specifically on quantifying FMEA severity scores for physics components of IMRT delivery and comparing to subjective scores. Methods: Eleven physical failure modes (FMs) for head and neck IMRT dose calculation and delivery are examined near commonly accepted tolerance criteria levels. Phantom treatment planning studies and dosimetry measurements (requiring decommissioning in several cases) are performed to determine the magnitude of dose delivery errors for the FMs (i.e., severity of the FM). Resultant quantitative severity scores are compared to FMEA scores obtained through an international survey and focus group studies. Results: Physical measurements for six FMs have resulted in significant PTV dose errors up to 4.3% as well as close to 1 mm significant distance-to-agreement error between PTV and OAR. Of the 129 survey responses, the vast majority of the responders used Varian machines with Pinnacle and Eclipse planning systems. The average years of experience was 17, yet familiarity with FMEA less than expected. Survey reports perception of dose delivery error magnitude varies widely, in some cases 50% difference in dose delivery error expected amongst respondents. Substantial variance is also seen for all FMs in occurrence, detectability, and severity scores assigned with average variance values of 5.5, 4.6, and 2.2, respectively. Survey shows for MLC positional FM(2mm) average of 7.6% dose error expected (range 0–50%) compared to 2% error seen in measurement. Analysis of ranking in survey, treatment planning studies, and quantitative value comparison will be presented. Conclusion: Resultant quantitative severity scores will expand the utility of FMEA for radiotherapy and verify accuracy of FMEA results compared to highly variable subjective scores.

60 APPLIED LIFE SCIENCES↗

SU-E-T-471: Small Field Jaw/MLC Reference Data

Purpose: In recent years the need for small field data of MLCs has increased due to the use of intensity-modulated radiation (IMRT), but moreover the use of stereotactic body radiation (SBRT) has increased, which uses not simply small field sizes, but small jaw and field sizes together. Having reference data for these small fields that is reliable would be invaluable to the physics community. Our study has gathered these values and the data distributions from the Radiological Physics Center's (RPC) site visits between 1990 and the present. Methods: For all measurements, the RPC used a 25 × 25 × 25cm water phantom placed at 100cm SSD. All measurements were made with an Exradin A16 cylindrical ion chamber at an effective depth of 10 cm. A total of 42 Varian machine measurements were used to compose the data for a 6 MV beam and 5 TrueBeam 6 MV flattening filter free (FFF) beams were used for FFF data. Results: Jaw/MLC fields were measured for both 6 MV and 6 MF FFF beams with the jaws and MLCs both at the following field sizes: 6×6, 4×4, 3×3, and 2×2cm. Measurements were normalized to the 10×10 field readings (defined by the jaws and MLC). Spread in the data was minimal and demonstrates a high level of accuracy of acquired data. Conclusion: Small field Jaw/MLC reference data for Varian 6MV and 6 MV FFF beams has been analyzed and presented here, composed of the aggregation of numerous RPC site visits. Obtaining reliable small field data remains difficult, however the RPC has collected high fidelity small field Jaw/MLC data. The data are presented as a reference along with their distributions, in such a way that the physicist can act based upon their own desired agreement with the reference data.

60 APPLIED LIFE SCIENCES↗

SU-E-T-509: Validation of the Use of OSLD for Carbon Beam Remote Dosimetry

Purpose: To describe the commissioning of Aluminum Oxide Optically Stimulated Luminescent Dosimeters (OSLD) for the use in Carbon beam remote dosimetry for centers participating in NCI-funded cooperative group clinical trials. Methods: As Carbon therapy centers express interest in participating in cooperative group clinical trials, the Imaging and Radiation Oncology Core Group (IROC) Houston QA Center (formerly RPC) is developing a way to remotely monitor the machine output of these Carbon facilities. OSLD have been commissioned for photon, electron and proton dosimetry, so an experiment was designed to commission the same dosimeters for Carbon. OSLD were irradiated in a Carbon therapy beam produced by the Siemens synchrotron at the Heidelberg Ion Therapy facility in Heidelberg, Germany. The OSLD were placed in acrylic phantoms, imaged with a CT scanner, and plans were developed using the Siemens treatment planning system. The OSLD were irradiated in uniform fields with maximum energies of 216, 301, and 402 MeV and at dose levels of 50, 100, 200 and 300 cGy. Results: The response of the OSLD in the Carbon beam, as compared to the Cobalt-60 reference condition, required an energy correction of 1.85 to account for the particle correction. OSLD dose calculations typically have a linearity correction to account for the change in response relative to the change in dose delivered. However, the response of the OSLD in the Carbon beam was found to be independent of the dose level; thus the linearity correction is 1.00. Conclusion: IROC Houston has commissioned OSLD for the use of remote output checks for Carbon therapy facilities to help ensure consistency across clinical trial participants. Work supported by grant CA10953 (NCI, DHHS)

07 ISOTOPE AND RADIATION SOURCES↗

SU-E-T-535: Preliminary 2D and 3D Gamma Calculation Comparison Using PRESAGE

Purpose: To compare gamma calculations from 2D and 3D dosimetry measurements for phantom quality assurance. Methods: An IROC Houston (RPC) head and neck phantom was irradiated with a 9 beam IMRT plan using two inserts: a TLD and film insert and a PRESAGE insert. Both inserts were irradiated 3 times. The film and PRESAGE doses were scaled to the TLD dose and 2D gamma calculations were made in the axial and sagittal planes bisecting the primary target. 3D gamma measurements were taken within the PRESAGE dosimeter volume. Gamma constraints of 3%/3mm distance to agreement (DTA), 5%/3mm DTA and 7%/4mm DTA were used in the study. The 3 irradiations for each insert were averaged together for comparison. Results: Film measurements for the 2D gamma showed 85% pixels passing at 3%/3mm in both planes. The 5%/3 mm constraint had 93% and 90% passing in the two planes. The 7%/4mm restraint resulted in 99% passing in both planes. The PRESAGE 2D gamma passed 66% and 61% of pixels in the both planes at 3%/3mm. At 5%/3mm 86% and 82% passed. For 7%/4mm, 94% of pixels passed in both planes. The 3D gamma resulted in a pass rate of 90% at 3%/3mm, 95% at 5%/3mm, and 99% at 7%/4mm. Conclusion: 2D gamma pass rates using film showed a higher pass rate than PRESAGE using the same criteria in the same planes. This may be due to poor 3D registration with the treatment plan compared to the 2D film registration system. The 3D gamma results had a higher pass rate (> 90% pass rate) possibly because it sampled many more pixels in noncritical volumes thus diluting the percent of pixels passing. 3D restraints should be more restrictive to be comparable to 2D results. Funding from NIH grant 5R01CA100835.

60 APPLIED LIFE SCIENCES↗